Bristol Myers Squibb is withdrawing the biopharmaceutical giant’s Istodax from the market after recent trials showed that the peripheral T-cell lymphoma drug did not achieve primary efficacy endpoint.

The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.

The U.S. Food and Drug Administration granted orphan drug designation to AFM13, Affimed N.V.’s lead CD30- and CD16A-binding innate cell engager, for the treatment of patients with T-cell lymphoma.